No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Coiled Therapeutics said on Tuesday that it had developed a next-generation lipid-based softgel formulation of AO-252, its first-in-class brain-penetrant TACC3 inhibitor, with first patient dosing expected in July 2026.
The AIM-traded company said the new formulation was designed to improve consistency and drug exposure at higher dose levels, addressing absorption limits seen with the current tablet.
It said the formulation supported its planned dose expansion cohorts in ovarian and prostate cancer, targeting enrolment of up to 30 patients by the fourth quarter.
Chief executive Sridhar Vempati said the softgel was "a key step in our dose expansion programme" and could "further strengthen AO-252's potential to deliver meaningful clinical outcomes."
At 0859 BST, shares in Coiled Therapeutics were up 4.74% at 9.95p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.